Current State of Dermatology Mobile Applications With Artificial Intelligence Features.

IF 11.5 1区 医学 Q1 DERMATOLOGY JAMA dermatology Pub Date : 2024-06-01 DOI:10.1001/jamadermatol.2024.0468
Shannon Wongvibulsin, Matthew J Yan, Vartan Pahalyants, William Murphy, Roxana Daneshjou, Veronica Rotemberg
{"title":"Current State of Dermatology Mobile Applications With Artificial Intelligence Features.","authors":"Shannon Wongvibulsin, Matthew J Yan, Vartan Pahalyants, William Murphy, Roxana Daneshjou, Veronica Rotemberg","doi":"10.1001/jamadermatol.2024.0468","DOIUrl":null,"url":null,"abstract":"<p><strong>Importance: </strong>With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applications (apps) claiming to aid in the assessment and management of diverse skin conditions. Despite widespread patient downloads, these apps exhibit limited evidence supporting their efficacy.</p><p><strong>Objective: </strong>To identify and characterize current English-language AI dermatology mobile apps available for download, focusing on aspects such as purpose, supporting evidence, regulatory status, clinician input, data privacy measures, and use of image data.</p><p><strong>Evidence review: </strong>In this cross-sectional study, both Apple and Android mobile app stores were systematically searched for dermatology-related apps that use AI algorithms. Each app's purpose, target audience, evidence-based claims, algorithm details, data availability, clinician input during development, and data usage privacy policies were evaluated.</p><p><strong>Findings: </strong>A total of 909 apps were initially identified. Following the removal of 518 duplicates, 391 apps remained. Subsequent review excluded 350 apps due to nonmedical nature, non-English languages, absence of AI features, or unavailability, ultimately leaving 41 apps for detailed analysis. The findings revealed several concerning aspects of the current landscape of AI apps in dermatology. Notably, none of the apps were approved by the US Food and Drug Administration, and only 2 of the apps included disclaimers for the lack of regulatory approval. Overall, the study found that these apps lack supporting evidence, input from clinicians and/or dermatologists, and transparency in algorithm development, data usage, and user privacy.</p><p><strong>Conclusions and relevance: </strong>This cross-sectional study determined that although AI dermatology mobile apps hold promise for improving access to care and patient outcomes, in their current state, they may pose harm due to potential risks, lack of consistent validation, and misleading user communication. Addressing challenges in efficacy, safety, and transparency through effective regulation, validation, and standardized evaluation criteria is essential to harness the benefits of these apps while minimizing risks.</p>","PeriodicalId":14734,"journal":{"name":"JAMA dermatology","volume":null,"pages":null},"PeriodicalIF":11.5000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10921342/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAMA dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1001/jamadermatol.2024.0468","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Importance: With advancements in mobile technology and artificial intelligence (AI) methods, there has been a substantial surge in the availability of direct-to-consumer mobile applications (apps) claiming to aid in the assessment and management of diverse skin conditions. Despite widespread patient downloads, these apps exhibit limited evidence supporting their efficacy.

Objective: To identify and characterize current English-language AI dermatology mobile apps available for download, focusing on aspects such as purpose, supporting evidence, regulatory status, clinician input, data privacy measures, and use of image data.

Evidence review: In this cross-sectional study, both Apple and Android mobile app stores were systematically searched for dermatology-related apps that use AI algorithms. Each app's purpose, target audience, evidence-based claims, algorithm details, data availability, clinician input during development, and data usage privacy policies were evaluated.

Findings: A total of 909 apps were initially identified. Following the removal of 518 duplicates, 391 apps remained. Subsequent review excluded 350 apps due to nonmedical nature, non-English languages, absence of AI features, or unavailability, ultimately leaving 41 apps for detailed analysis. The findings revealed several concerning aspects of the current landscape of AI apps in dermatology. Notably, none of the apps were approved by the US Food and Drug Administration, and only 2 of the apps included disclaimers for the lack of regulatory approval. Overall, the study found that these apps lack supporting evidence, input from clinicians and/or dermatologists, and transparency in algorithm development, data usage, and user privacy.

Conclusions and relevance: This cross-sectional study determined that although AI dermatology mobile apps hold promise for improving access to care and patient outcomes, in their current state, they may pose harm due to potential risks, lack of consistent validation, and misleading user communication. Addressing challenges in efficacy, safety, and transparency through effective regulation, validation, and standardized evaluation criteria is essential to harness the benefits of these apps while minimizing risks.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
具有人工智能功能的皮肤科移动应用现状:范围综述。
重要性:随着移动技术和人工智能(AI)方法的进步,直接面向消费者的移动应用程序(Apps)大幅增加,这些应用程序声称可帮助评估和管理各种皮肤状况。尽管这些应用程序被患者广泛下载,但支持其功效的证据却很有限:识别并描述目前可供下载的英语人工智能皮肤病学移动应用程序,重点关注目的、支持证据、监管状态、临床医生输入、数据隐私措施和图像数据使用等方面:在此次范围审查中,我们系统地搜索了苹果和安卓手机应用商店中使用人工智能算法的皮肤病学相关应用。对每个应用程序的目的、目标受众、循证声明、算法细节、数据可用性、临床医生在开发过程中的投入以及数据使用隐私政策进行了评估:最初共确定了 909 个应用程序。在删除了 518 个重复的应用程序后,还剩下 391 个应用程序。随后的审查由于非医疗性质、非英语语言、缺乏人工智能功能或不可用等原因排除了 350 个应用程序,最终剩下 41 个应用程序可供详细分析。研究结果揭示了当前皮肤科人工智能应用程序的几个令人担忧的方面。值得注意的是,没有一款应用程序获得美国食品和药物管理局的批准,其中只有两款应用程序包含未经监管部门批准的免责声明。总体而言,研究发现这些应用程序缺乏支持性证据、临床医生和/或皮肤科医生的意见,以及算法开发、数据使用和用户隐私方面的透明度:本次范围界定审查确定,尽管人工智能皮肤科移动应用程序有望改善医疗服务的可及性和患者预后,但就其现状而言,它们可能会因潜在风险、缺乏一致验证和误导性用户沟通而造成危害。通过有效的监管、验证和标准化的评估标准来应对疗效、安全性和透明度方面的挑战,对于利用这些应用程序的优势同时最大限度地降低风险至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
JAMA dermatology
JAMA dermatology DERMATOLOGY-
CiteScore
14.10
自引率
5.50%
发文量
300
期刊介绍: JAMA Dermatology is an international peer-reviewed journal that has been in continuous publication since 1882. It began publication by the American Medical Association in 1920 as Archives of Dermatology and Syphilology. The journal publishes material that helps in the development and testing of the effectiveness of diagnosis and treatment in medical and surgical dermatology, pediatric and geriatric dermatology, and oncologic and aesthetic dermatologic surgery. JAMA Dermatology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications. It is published online weekly, every Wednesday, and in 12 print/online issues a year. The mission of the journal is to elevate the art and science of health and diseases of skin, hair, nails, and mucous membranes, and their treatment, with the aim of enabling dermatologists to deliver evidence-based, high-value medical and surgical dermatologic care. The journal publishes a broad range of innovative studies and trials that shift research and clinical practice paradigms, expand the understanding of the burden of dermatologic diseases and key outcomes, improve the practice of dermatology, and ensure equitable care to all patients. It also features research and opinion examining ethical, moral, socioeconomic, educational, and political issues relevant to dermatologists, aiming to enable ongoing improvement to the workforce, scope of practice, and the training of future dermatologists. JAMA Dermatology aims to be a leader in developing initiatives to improve diversity, equity, and inclusion within the specialty and within dermatology medical publishing.
期刊最新文献
COVID-19 as a Risk Factor For Autoimmune Skin Disease. Long-Term Risk of Autoimmune and Autoinflammatory Connective Tissue Disorders Following COVID-19. Madelung Disease. Psoriasis Risk With Immune Checkpoint Inhibitors. Use of Anti-PD1 Blockade After Hedgehog Inhibitors or as First-Line Therapy for Gorlin Syndrome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1